Martin Driscoll is the founder of Onconano Medicine. Onconano Medicine has raised $68M in total funding. Latest round: Series B. Backed by CPRIT.
Martin Driscoll is the Chief Executive Officer of OncoNano Medicine, a company developing products that exploit pH as a biomarker to diagnose and treat cancer. He joined OncoNano Medicine in February 2021. Prior to this role, Mr. Driscoll served as President and Chief Executive Officer of Spring Bank Pharmaceuticals and has led several biopharmaceutical development companies.
Full founder directory · Investor directory · Company funding database · Fundraising library